InvestorsHub Logo
icon url

The Other Guy

10/25/17 11:20 AM

#315404 RE: biopharm #315403

Yep, hopefully the IP can be sold for maximum value. I doubt Johnson/Swartz/Pohl can do it.

What is Steve King going to do when the R&D is sold off? Please don’t tell me he is part of the deal. If anything, adding Steve in with the sale of the IP would devalue it. Us shareholders want maximum value!
icon url

ku

10/25/17 12:04 PM

#315419 RE: biopharm #315403

Because Peregrine does not have the right management team to get the job done. Refresher:

Shares BOD owned before Reverse Split and their yearly Salaries:

Eric Swartz 96,017 Shares 518,000 Dollars
David Pohl 286 Shares 488,000 Dollars
Carlton Johnson 1095 Shares 548,000 Dollars
Attending a few conference calls
Does the above mean that they care about the company and us ?????

And some of us have been thru 2 Reverse Splits.